Inge Marie Svane

Inge Marie Svane

Clinical Professor

Member of:

  • Clinical Oncology

ORCID: 0000-0002-9451-6037

Publication year:
All
61 - 70 out of 273Page size: 10
  1. 2021
  2. Published

    An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma

    Klausen, U., Grønne Dahlager Jørgensen, N., Grauslund, J. H., Munir Ahmad, S., Gang, Anne Ortved, Martinenaite, E., Weis-Banke, S. E., Breinholt, M. F., Novotny, G. W., Kjeldsen, J. W., Orebo Holmström, M., Pedersen, L. B., Poulsen, C. B., Hansen, P. B., Met, Özcan, Svane, Inge Marie, Niemann, Carsten, Pedersen, Lars Møller & Andersen, Mads Hald, 2021, In: OncoImmunology. 10, 1, 1975889.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma

    Borch, T. H., Harbst, K., Rana, A. H., Andersen, R., Martinenaite, E., Kongsted, P., Pedersen, M., Nielsen, M., Kjeldsen, J. W., Kverneland, Anders Handrup, Lauss, M., Hølmich, Lisbet Rosenkrantz, Hendel, Helle Westergren, Met, Özcan, Jönsson, G., dqp123, dqp123 & Svane, Inge Marie, 2021, In: Journal for ImmunoTherapy of Cancer. 9, 7, 15 p., e00270.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Comparison of efficacy in patients with metastatic melanoma treated with ipilimumab and nivolumab who did or did not discontinue treatment due to immune-related adverse events: A real-world data study

    Fink, M., Vittrup, A. S., Bastholt, L., Svane, Inge Marie, dqp123, dqp123, Luczak, A. A., Ruhlmann, C. H., Guldbrandt, L. M., Koehler, U. H., Winther, M. L., Ellebaek, E., Haslund, C. A. & Schmidt, H., 2021, In: Cancers. 13, 21, 10 p., 5550.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

    Eggermont, A. M. M., Meshcheryakov, A., Atkinson, V., Blank, C. U., Mandala, M., Long, G. V., Barrow, C., Di Giacomo, A. M., Fisher, R., Sandhu, S., Kudchadkar, R., Romero, P. L. O., Svane, I. M., Larkin, J., Puig, S., Hersey, P., Quaglino, P., Queirolo, P., Stroyakovskiy, D., Bastholt, L. & 14 others, Mohr, P., Hernberg, M., Chiarion-Sileni, V., Strother, M., Hauschild, A., Yamazaki, N., van Akkooi, A. C., Lorigan, P., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S. & Robert, C., 2021, In: European Journal of Cancer. 158, p. 156-168 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Laser immunotherapy: A potential treatment modality for keratinocyte carcinoma

    Omland, S. H., Wenande, E. C., Svane, Inge Marie, Tam, J., Olesen, U. H. & Hædersdal, Merete, 2021, In: Cancers. 13, 21, 18 p., 5405.

    Research output: Contribution to journal › Review › Research › peer-review

  7. Published

    Lynch syndrome-associated epithelial ovarian cancer and its immunological profile

    Rasmussen, M., Lim, K., Rambech, E., Andersen, Mads Hald, Svane, Inge Marie, Andersen, Ove, Jensen, L. H., Nilbert, Mef Christina & Therkildsen, C., 2021, In: Gynecologic Oncology. 162, 3, p. 686-693

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation

    Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., Ioannidou, K., Castro, W., Neal, C., Moriot, A., Renaud-Tissot, S., Anstett, V., Fahr, N., Tanyi, J. L., Eiva, M. A., Jacobson, C. A. & 16 others, Montone, K. T., Westergaard, M. C. W., Svane, Inge Marie, Kandalaft, L. E., Delorenzi, M., Sorger, P. K., Färkkilä, A., Michielin, O., Zoete, V., Carmona, S. J., Foukas, P. G., Powell, D. J., Rusakiewicz, S., Doucey, M. A., Dangaj Laniti, D. & Coukos, G., 2021, In: Cancer Cell. 39, 12, p. 1623-1642.e20

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNϒ, Following Recognition of Autologous Tumor-Antigens

    Draghi, A., Chamberlain, C. A., Khan, S., Papp, K., Lauss, M., Soraggi, S., Radic, H. D., Presti, M., Harbst, K., Gokuldass, A., Kverneland, Anders Handrup, Nielsen, M., Westergaard, M. C. W., Andersen, Mads Hald, Csabai, I., Jönsson, G., Szallasi, Z., Svane, Inge Marie & dqp123, dqp123, 2021, In: Frontiers in Immunology. 12, 13 p., 705422.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Real-time monitoring of mitochondrial respiration in cytokine-differentiated human primary T cells

    Mølgaard, K., Rahbech, A., Met, Özcan, Svane, Inge Marie, Straten, P., Desler, Claus & Peeters, M. J. W., 2021, In: Journal of Visualized Experiments. 176, e62984.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56

    Holmen Olofsson, G., Pedersen, S. R., Aehnlich, P., Svane, Inge Marie, Idorn, M. & thor Straten, P., 2021, In: Cytotherapy. 23, 7, p. 582-589

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...3 4 5 6 7 8 9 10 ...28 Next

ID: 4054758